Willis Towers Watson PLC reported first‑quarter 2026 results that included a revenue of $2.41 billion, an 8% year‑over‑year increase and a 4% rise on a constant‑currency basis. Adjusted diluted earnings per share reached $3.72, beating consensus estimates of $3.66–$3.67 by $0.05–$0.06 and reflecting a 3% organic revenue growth. Operating margin expanded by 70 basis points to 22.3%, driven by efficiency gains and a favorable mix shift across the company’s Health, Wealth & Career and Risk & Broking segments. The firm also repurchased $300 million of shares during the quarter, underscoring its commitment to returning capital to investors while maintaining a strong balance sheet.
Revenue growth was supported by a 3% increase in organic sales, but the company’s top line fell short of the $2.42–$2.45 billion consensus range. Compared with Q4 2025, revenue was $2.94 billion, and with Q1 2025, $2.22 billion, indicating a deceleration in growth momentum. The constant‑currency gain of 4% reflects favorable foreign‑exchange movements that partially offset the lower domestic demand.
Operating margin expansion to 22.3% from 21.6% in the prior year was largely a result of disciplined cost control and a shift toward higher‑margin business. The company’s focus on efficiency, as highlighted by CEO Carl Hess, “helped us generate operating leverage and 70 basis points of year‑over‑year margin expansion,” underscoring the effectiveness of its cost‑management initiatives.
Segment‑level analysis shows that the Health, Wealth & Career division grew 3% organically, driven by strength in Health and Wealth, while the Career sub‑segment declined due to clients deferring discretionary work amid geopolitical uncertainty in the Middle East. The Risk & Broking segment posted 2% organic growth, slowed by new‑business timing and competitive pricing pressures. These dynamics explain the mixed performance across the company’s core lines of business.
Management maintained its full‑year 2026 organic revenue guidance in the mid‑single‑digit range but narrowed its Corporate Risk & Broking outlook to mid‑single digits. The company reiterated confidence in its AI and technology investments, including the Newfront acquisition, which is expected to be dilutive to adjusted EPS in 2026. The firm also announced a $300 million share‑repurchase program for the quarter, reinforcing its capital‑allocation strategy.
Investors focused on the revenue miss and the slower‑than‑expected organic growth, which tempered enthusiasm for the earnings beat. The lack of a clear full‑year guidance update and the anticipated headwinds from the Willis Re joint venture and the Newfront acquisition contributed to a cautious market reaction.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.